The Cure Alliance Press Releases - EIN Presswire - Press Release Distribution Service

Published on October 27, 2025 - 10:00 GMT

First 5 Patients with 'Brittle' T1D are Insulin-Free

Breaking News from 2025 Congress of Cell Transplantation and Regenerative Medicine Society TOKYO, JAPAN, October 27, 2025 /⁨EINPresswire.com⁩/ -- At the 2025 Congress of the Cell Transplant and Regenerative Medicine Society Saturday, world-renowned expert …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...

Published on October 29, 2024 - 10:00 GMT

First Three Patients with T1D Successfully Transplanted with Novel Antibody to Eliminate Harsh Anti-rejection Drug

Stunning Results of First Human Trials Presented Today in Boston at 5th Summit on Stem Cell Derived Islets MIAMI, FL, UNITED STATES, October 29, 2024 /⁨EINPresswire.com⁩/ -- The Cure Alliance, a 501(c)(3) nonprofit, is excited to announce that three …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on May 8, 2024 - 10:00 GMT

U of Chicago Docs Perform First Human Islet Transplant Successfully Using Antibody To Replace Toxic Anti-Rejection Drug

A critical step to cure millions with diabetes: Chicago woman is first to have successful human islet transplant using novel antibody to prevent rejection. MIAMI, FLORIDA, USA, May 8, 2024 /⁨EINPresswire.com⁩/ -- The Cure Alliance, a 501(c)(3) nonprofit, …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on October 16, 2023 - 21:35 GMT

The Cure Alliance Sends Key Funding For 1st Human Islet Transplant Using Novel Drug to Replace Toxic Anti-Rejection Drug

U of Chicago to use novel antibody to replace tacrolimus, the harsh anti-rejection drug associated with increased risk of severe side effects. MIAMI, FLORIDA, UNITED STATES, October 16, 2023 /⁨EINPresswire.com⁩/ -- The Cure Alliance, a 501(c)(3) …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on July 5, 2023 - 00:00 GMT

The Cure Alliance Gets IRB Approval for "C3" Clinical Trial To Treat Deadliest Pancreatic Cancer AT SUNY Downstate

"C3," a Combination of 3 Generic Drugs Designed to Halt Advanced Adenocarcinoma Pancreatic Cancer Moves from the Lab to Human Trials MIAMI, FLORIDA, UNITED STATES, July 4, 2023 /⁨EINPresswire.com⁩/ -- The Cure Alliance, 501(c)(3) non-profit, …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...